| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Nicoform targets microbial growth as an antimicrobial agent. It also interacts with the thyroid hormone receptor and steroid receptor coregulator 2 (SRC2) with a potency of 3981.1 nM. As a precursor to NAD, it is involved in cellular redox reactions and energy metabolism. The compound has choleretic effects, promoting bile secretion and relieving sphincter spasm.
|
|---|---|
| ln Vitro |
In vitro, Nicoform (N-(Hydroxymethyl)nicotinamide) has been tested for its ability to inhibit the interaction between the thyroid hormone receptor and steroid receptor coregulator 2 with an IC₅₀ of 3981.1 nM. It exhibits antimicrobial activity against bacteria and fungi. As a NAD precursor, it supports cellular metabolism. The compound's activity in various biochemical assays has been characterized. Detailed in vitro data are available in the primary literature.
|
| ln Vivo |
In vivo, Nicoform (N-(Hydroxymethyl)nicotinamide) acts as a choleretic and hepatoprotective agent. It relieves sphincter spasm, promotes bile secretion, increases bile water content, dilutes bile, and enhances gallbladder contraction. It may help prevent fatty liver degeneration. It is used in the treatment of biliary tract disorders. The compound also has antimicrobial properties.
|
| Enzyme Assay |
In vitro antimicrobial assays for Nicoform typically involve broth microdilution or agar diffusion methods against bacterial and fungal strains. The compound is dissolved in DMSO or appropriate solvent and serially diluted in growth medium. Microbial cultures are inoculated and incubated at 37°C for 18-24 hours. Minimum inhibitory concentration (MIC) is determined as the lowest concentration inhibiting visible growth. Controls include vehicle and known antibiotics. Assays are performed in duplicate or triplicate.
|
| Cell Assay |
For cell-based assays, relevant cell lines (e.g., hepatocytes or thyroid receptor-expressing cells) are cultured in appropriate medium. Cells are seeded in 96-well plates and treated with Nicoform at various concentrations for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo. Gene expression changes related to thyroid hormone signaling may be measured by RT-PCR or reporter assays. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Nicoform (N-(Hydroxymethyl)nicotinamide) is typically administered orally to patients or animals. For choleretic studies, bile flow is measured after administration. For hepatoprotective studies, liver enzyme levels (ALT, AST) and histopathology are assessed. The compound is used in clinical practice in some countries. Dosing regimens are established based on clinical use. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
Nicoform (MW 152.15, C₇H₈N₂O₂) is soluble in DMSO (30 mg/mL). It is a prodrug that is metabolized to nicotinamide and formaldehyde in the body. Pharmacokinetic properties have been characterized in clinical studies. The compound is absorbed orally and distributed to tissues. It is excreted in urine as metabolites. Detailed PK parameters are available from pharmaceutical references.
|
| Toxicity/Toxicokinetics |
Nicoform is generally well-tolerated at therapeutic doses. As a choleretic and hepatoprotective agent, it has a favorable safety profile. Adverse effects are rare. The compound is approved for use as a drug in some countries. Standard precautions should be followed. The compound is for research and clinical use.
|
| Additional Infomation |
Hydroxymethylnicotinamide is a pyridine carboxamide. It is functionally related to nicotinamide.
Nicoform (N-(Hydroxymethyl)nicotinamide, Bilamid) is a choleretic, hepatoprotective, and antimicrobial agent. It is used in the treatment of biliary tract disorders and as a liver protectant. The compound is also a NAD precursor. It is approved as a drug in some countries and available from pharmaceutical suppliers. Its mechanism involves choleretic and antimicrobial activities. |
| Molecular Formula |
C7H8N2O2
|
|---|---|
| Molecular Weight |
152.1506
|
| Exact Mass |
152.058
|
| CAS # |
3569-99-1
|
| PubChem CID |
77116
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
427.7±25.0 °C at 760 mmHg
|
| Melting Point |
152-154 °C(lit.)
|
| Flash Point |
212.5±23.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])([H])N([H])C(C1=C([H])N=C([H])C([H])=C1[H])=O
|
| InChi Key |
JRFKIOFLCXKVOT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8N2O2/c10-5-9-7(11)6-2-1-3-8-4-6/h1-4,10H,5H2,(H,9,11)
|
| Chemical Name |
N-(hydroxymethyl)pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~657.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5725 mL | 32.8623 mL | 65.7246 mL | |
| 5 mM | 1.3145 mL | 6.5725 mL | 13.1449 mL | |
| 10 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
